Amgen Inc. (AMGN) Shareholder Equity
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-119.00M; Retained Earnings (Accumulated Deficit)USD $-22.27B; Stockholders' Equity Attributable to ParentUSD $11.69B; APIC, Share-based Payment Arrangement, Increase for Cost RecognitionUSD 3 month · $165.00M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-190.00M; Retained Earnings (Accumulated Deficit)USD $-24.65B; Stockholders' Equity Attributable to ParentUSD $9.19B; APIC, Share-based Payment Arrangement, Increase for Cost RecognitionUSD 3 month · $75.00M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-258.00M; Retained Earnings (Accumulated Deficit)USD $-25.11B; Stockholders' Equity Attributable to ParentUSD $8.66B; APIC, Share-based Payment Arrangement, Increase for Cost RecognitionUSD 12 month · $494.00M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-422.00M; Retained Earnings (Accumulated Deficit)USD $-23.80B; Stockholders' Equity Attributable to ParentUSD $9.62B; APIC, Share-based Payment Arrangement, Increase for Cost RecognitionUSD 3 month · $127.00M.
Amgen Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Common Stocks, Including Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-119.00M | $-22.27B | $11.69B | 3 month · $165.00M 6 month · $240.00M | $34.08B | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-190.00M | $-24.65B | $9.19B | 3 month · $75.00M | $34.03B | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-258.00M | $-25.11B | $8.66B | 12 month · $494.00M | $34.02B | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-422.00M | $-23.80B | $9.62B | 3 month · $127.00M 9 month · $369.00M | $33.84B | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-544.00M | $-25.71B | $7.43B | 3 month · $157.00M 6 month · $242.00M | $33.68B | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-231.00M | $-27.14B | $6.21B | 3 month · $85.00M | $33.58B | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-66.00M | $-27.59B | $5.88B | 12 month · $530.00M | $33.53B | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-336.00M | $-25.53B | $7.53B | 3 month · $136.00M 9 month · $396.00M | $33.39B | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-155.00M | $-27.12B | $5.92B | 3 month · $157.00M 6 month · $260.00M | $33.20B | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-190.00M | $-27.87B | $5.02B | 3 month · $103.00M | $33.08B | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-289.00M | $-26.55B | $6.23B | 12 month · $454.00M | $33.07B | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-126.00M | $-24.97B | $7.66B | 3 month · $124.00M | $32.75B | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-280.00M | $-25.54B | $6.78B | 3 month · $119.00M | $32.60B | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-268.00M | $-26.92B | $5.35B | 3 month · $47.00M | $32.53B | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-231.00M | $-28.62B | $3.66B | 12 month · $419.00M | $32.51B | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-652.00M | $-28.07B | $3.65B | 3 month · $121.00M | $32.37B | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-672.00M | $-28.25B | $2.42B | 3 month · $120.00M | $31.34B | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-763.00M | $-29.57B | $916.00M | 3 month · $78.00M | $31.25B | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-796.00M | $-24.60B | $6.70B | 12 month · $361.00M | $32.10B | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-808.00M | $-22.96B | $8.22B | 3 month · $111.00M | $31.99B | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-868.00M | $-22.76B | $8.25B | 3 month · $100.00M | $31.88B | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-833.00M | $-21.64B | $9.33B | 3 month · $57.00M | $31.81B | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-985.00M | $-21.41B | $9.41B | 12 month · $349.00M | $31.80B | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-903.00M | $-19.85B | $10.96B | 3 month · $109.00M | $31.71B | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-783.00M | $-20.17B | $10.66B | 3 month · $101.00M | $31.61B | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-662.00M | $-21.38B | $9.48B | 3 month · $52.00M | $31.52B | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-528.00M | $-21.33B | $9.67B | 12 month · $323.00M | $31.53B | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $-388.00M | $-20.14B | $10.93B | 3 month · $108.00M | $31.45B | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-465.00M | $-20.05B | $10.79B | 3 month · $97.00M | $31.31B | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-516.00M | $-19.89B | $10.83B | 3 month · $64.00M | $31.24B | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-769.00M | $-17.98B | $12.50B | 12 month · $327.00M | $31.25B | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $-809.00M | $-15.99B | $14.35B | 3 month · $94.00M | $31.14B | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-873.00M | $-15.27B | $14.91B | 3 month · $93.00M | $31.05B | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-994.00M | $-14.39B | $15.62B | 3 month · $61.00M | $31.00B | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-679.00M | $-5.07B | $25.24B | 12 month · $347.00M | $30.99B | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-443.00M | $1.77B | $32.23B | (m) | $30.90B | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $-449.00M | $1.38B | $31.72B | (m) | $30.79B | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $-362.00M | $233.00M | $30.64B | (m) | $30.77B | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-471.00M | $-438.00M | $29.88B | 12 month · $342.00M | $30.78B | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $-139.00M | $221.00M | $30.77B | (m) | $30.69B | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $-106.00M | $-356.00M | $30.13B | (m) | $30.59B | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $-268.00M | $-1.64B | $28.68B | (m) | $30.59B | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-480.00M | $-2.09B | $28.08B | 12 month · $319.00M | $30.65B | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $-237.00M | $-2.35B | $27.97B | (m) | $30.56B | $-505.00M | $-22.00M | (m) | $300.00M | (m) |
| 2015-06-30 | $-68.00M | $-2.91B | $27.48B | (m) | $30.46B | $-419.00M | $13.00M | (m) | $353.00M | (m) |
| 2015-03-31 | $137.00M | $-4.05B | $26.51B | (m) | $30.42B | $-437.00M | $121.00M | (m) | $468.00M | (m) |
| 2014-12-31 | $-8.00M | $-4.62B | $25.78B | 12 month · $404.00M | $30.41B | $-264.00M | $-19.00M | (m) | $290.00M | (m) |
| 2014-09-30 | $-104.00M | $-4.70B | $25.32B | (m) | $30.13B | $-193.00M | $-76.00M | (m) | $172.00M | (m) |
| 2014-06-30 | $-123.00M | $-5.48B | $24.38B | (m) | $29.98B | $-69.00M | $18.00M | (m) | $-56.00M | (m) |
| 2014-03-31 | $-126.00M | $-7.02B | $22.74B | (m) | $29.89B | $-76.00M | $-3.00M | (m) | $-31.00M | (m) |
| 2013-12-31 | $-161.00M | $-7.63B | $22.10B | 12 month · $400.00M | $29.89B | $-68.00M | $-43.00M | 12 month · $99.00M | $-33.00M | (m) |
| 2013-09-30 | $-97.00M | $-7.84B | $21.73B | (m) | $29.66B | $-24.00M | $-36.00M | (m) | $-22.00M | (m) |
| 2013-06-30 | $-71.00M | $-8.85B | $20.59B | (m) | $29.52B | $-36.00M | $-84.00M | (m) | $62.00M | (m) |
| 2013-03-31 | $137.00M | $-10.11B | $19.49B | (m) | (m) | $-11.00M | $121.00M | (m) | $40.00M | (m) |
| 2012-12-31 | $146.00M | $-10.42B | $19.06B | 12 month · $359.00M | $29.34B | $12.00M | $183.00M | (m) | $-35.00M | (m) |
| 2012-09-30 | $147.00M | $-9.35B | $19.90B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $151.00M | $-9.38B | $19.24B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $106.00M | $-9.44B | $18.87B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $171.00M | $-8.92B | $19.03B | 12 month · $337.00M | (m) | $21.00M | $120.00M | (m) | $43.00M | (m) |
| 2011-09-30 | $118.00M | $-4.17B | $23.55B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $45.00M | $-1.95B | $25.61B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $-9.00M | $-2.38B | $24.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $153.00M | $-3.51B | $23.94B | 12 month · $357.00M | (m) | $22.00M | $135.00M | (m) | $3.00M | 12 month · $-71.00M |
| 2010-09-30 | $255.00M | $-3.39B | $24.07B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $317.00M | $-4.27B | $23.17B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $160.00M | $-4.85B | $22.34B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $45.00M | $-4.32B | $22.67B | 12 month · $324.00M | (m) | $40.00M | $95.00M | (m) | $-82.00M | 12 month · $-11.00M |
| 2009-09-30 | $47.00M | $-4.04B | $22.86B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | $63.00M | $-5.42B | $21.36B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $117.00M | $-5.67B | $20.89B | 12 month · $267.00M | (m) | $25.00M | $49.00M | (m) | $50.00M | 12 month · $86.00M |
| 2007-12-31 | $53.00M | (m) | $18.51B | 12 month · $316.00M | (m) | $59.00M | $39.00M | (m) | $-45.00M | 12 month · $26.00M |
| 2006-12-31 | (m) | (m) | $19.84B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |